October 26, 2021 Portfolio News from ARCH Venture Partners | Share Mozart Therapeutics makes its official debut, jumping into the hot Treg R&D field with ARCH Venture backing it
October 7, 2021 Portfolio News from ARCH Venture Partners | Share ARCH unveils Neumora, its Really Big Neuroscience Company, with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more
September 22, 2021 Media Coverage from ARCH Venture Partners | Share ARCH-backed Dewpoint, eGenesis and Prime Medicine named to Endpoints 11 Most Promising Biopharma Startups in 2021
August 25, 2021 Portfolio News from ARCH Venture Partners | Share Recuro Health Announces Its $15 Million Series A Round Led by ARCH Venture Partners
July 29, 2021 Portfolio News from ARCH Venture Partners | Share bluebird bio and National Resilience Ink Cell Therapy Strategic Alliance
July 26, 2021 Media Coverage from ARCH Venture Partners | Share ARCH adds FDA, biodefense expertise with appointment of Luciana Borio
July 22, 2021 Portfolio News from ARCH Venture Partners | Share Slingshot Launches with $23 Million for Synthetic Cell Products
July 19, 2021 Portfolio News from ARCH Venture Partners | Share Rome, backed by Arch and GV, hires science leaders to hit targets in “junk DNA”
July 14, 2021 Portfolio News from ARCH Venture Partners | Share Prime Medicine raises $315M to fuel ‘search-and-replace’ gene editing work
June 2, 2021 Media Coverage from ARCH Venture Partners | Share Global Business Reports: U.S. Pharmaceutical and Biopharmaceutical Industry Report. An interview with Keith Crandell.
May 15, 2021 Portfolio News from ARCH Venture Partners | Share ARCH Co-leads Investment for Interline, Precision Medicine Platform
April 28, 2021 Portfolio News from ARCH Venture Partners | Share New Antibody Therapy And Prophylactic Shows Promise In Defending Against SARS-CoV-2 Variants Of Concern
